Zilovertamab vedotin

ASH 2024 highlights include GSK's Blenrep Phase 3 data supporting re-market, J&J's Darzalex Faspro delaying progression in smoldering multiple myeloma, Arcellx's anito-cel showing comparable safety to Carvykti, and J&J/Legend's Carvykti improving survival outcomes. Kura Oncology's ziftomenib showed high response rates in leukemia, Eli Lilly's Jaypirca reduced disease progression risk, and Merck's zilovertamab vedotin achieved high complete response rates in lymphoma. Beam Therapeutics' BEAM-101 showed durable effects in sickle cell disease, Novo Nordisk's etavopivat reduced crises, and Bristol Myers Squibb's arlo-cel demonstrated durable responses in multiple myeloma. Galapagos' GLPG5101 showed encouraging cell therapy results, Orca Bio's Orca-T improved survival in blood cancers, and Sanofi's rilzabrutinib improved platelet response in thrombocytopenia. Regeneron's drug combo showed better disease control than Ultomiris in PNH.

Merck presented Phase II waveLINE-007 trial results at ASH, showing zilovertamab vedotin (ROR1 ADC) with R-CHP achieved 94.4% CR in first-line DLBCL, higher than R-Pola-CHP (78%) and R-CHOP (74%). Merck plans a Phase III trial vs. R-CHOP, but considering R-Pola-CHP's market growth, using it as control may be more strategic.

Zilovertamab vedotin plus R-CHP showed high response rates (97.2% ORR, all CRs) in DLBCL patients across various doses in the WAVELINE-007 trial. The RP2D of 1.75 mg/kg every 3 weeks achieved 100% ORR (all CRs). Median duration of response was not reached, with 12-month DOR at 93.5% across all doses. A manageable safety profile was observed, with a phase 3 study (waveLINE-010) planned to compare zilovertamab vedotin/R-CHP with R-CHOP in untreated DLBCL.

Darzalex reduced smoldering multiple myeloma progression risk by 51%; BEAM-101 increased fetal hemoglobin in sickle cell patients; zilovertamab vedotin achieved complete responses in lymphoma; etavopivat halved sickle cell pain crises; anito-cel showed strong response in multiple myeloma, with potential to surpass existing therapies.

Merck's Phase II waveLINE-007 study shows zilovertamab vedotin, an antibody-drug conjugate, achieved a 100% complete response rate in treating diffuse large B cell lymphoma at 1.75 mg/kg dose with R-CHP regimen. Safety concerns include grade 3-4 adverse events in 58% of patients, with 11% experiencing serious toxicities. Merck plans to advance the 1.75 mg/kg dose to Phase III testing.

Merck announced Phase 2 waveLINE-007 trial data showing zilovertamab vedotin, an ADC targeting ROR1, achieved a 100% complete response rate in previously untreated DLBCL patients at a 1.75 mg/kg dose, establishing this as the recommended Phase 3 dose.

Zilovertamab vedotin plus R-CHP achieved 100% complete response (CR) in previously untreated diffuse large B cell lymphoma (DLBCL) patients, with a manageable safety profile, according to the WAVELINE-007 trial presented at ASH 2024.

Merck's Phase 2 waveLINE-007 trial achieved a 100% complete response rate with zilovertamab vedotin (1.75 mg/kg) combined with R-CHP for previously untreated DLBCL, establishing this dose as the recommended Phase 3 dose. The trial enrolled 36 patients, with a total complete response rate of 97.2% and a 12-month duration of response of 93.5%. Serious treatment-related adverse events occurred in 11% of patients, and Grade 3-4 events in 58%.

Merck's Phase 2 waveLINE-007 trial shows zilovertamab vedotin, an investigational ADC targeting ROR1, in combination with R-CHP achieved a 100% complete response rate at 1.75 mg/kg in previously untreated diffuse large B-cell lymphoma patients, establishing this dose as the recommended Phase 3 dose.

DelveInsight's follicular lymphoma pipeline report highlights 50+ companies developing 55+ therapies, including key players like Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, and others. Promising therapies such as Parsaclisib, TQ-B3525, and Tafasitamab are in various clinical trial phases. Notable events include Incyte's acquisition of tafasitamab rights and Janssen's collaboration with CBMG for CAR-T therapies.